孤立性7号染色体部分或完全缺失的骨髓增生异常综合征患者的体细胞突变影响
该研究对280例以-7/del(7q)为唯一细胞遗传学异常的MDS患者进行深度靶向突变筛查,发现79%可检出体细胞突变,中位突变数为2个。≥2个突变者24个月白血病转化率高于<2个或无突变者(38% vs 20%,p=0.044)。未治疗del(7q)患者中位OS优于-7(34 vs 17个月,p=0.034)。多因素分析中原始细胞数、TP53突变和突变数目是OS独立预测因素,细胞遗传学亚组失去预后意义。
要点
- 孤立性-7/del(7q)的MDS患者中79%可检出体细胞突变。
- ≥2个突变者24个月白血病转化风险高于<2个或无突变者。
- 多因素分析中TP53突变和突变数目是OS独立预测因素。
核心结论
- 在孤立性-7/del(7q)的MDS患者中,体细胞突变分析对预后判断具有重要意义。
- 多因素分析显示原始细胞数、TP53突变和突变数目是OS的独立预测因素,而细胞遗传学亚组未保留预后相关性。
研究设计与样本
- 对280例以-7/del(7q)为唯一细胞遗传学异常的MDS患者进行深度靶向突变筛查,其中del(7q) 86例、-7 194例。
- 117例患者进行了体细胞突变检测,其中-7组82%、del(7q)组73%检出突变。
- 每例患者中位突变数为2个(范围0-8)。
主要发现
- del(7q)与-7两组在人口学和疾病相关特征上相似,突变频率无差异。
- ≥2个突变者24个月白血病转化率为38%,<2个或无突变者为20%(p=0.044)。
- 未治疗del(7q)患者中位OS为34个月,-7患者为17个月(p=0.034)。
临床怎么用
- 对孤立性-7/del(7q)的MDS患者应进行体细胞突变检测以辅助预后分层。
- 突变数目≥2和TP53突变可提示更差预后,需结合原始细胞数综合评估。
局限性
- 体细胞突变检测仅在117/280例患者中进行,存在样本可及性限制。
- 原文未报告多因素分析的具体风险比及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monosomy 7 [-7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with -7/del(7q) as isolated cytogenetic abnormality (86 with del(7q) and 194 with -7). Patients with del(7q) or -7 had similar demographic and disease-related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in -7 and 73% in del(7q) group). Median number of mutations per patient was 2 (range 0-8). There was no difference in mutation frequency between the two groups. Patients harbouring ≥2 mutations had a worse outcome than patients with <2 or no mutations (leukaemic transformation at 24 months, 38% and 20%, respectively, p = 0.044). Untreated patients with del(7q) had better overall survival (OS) compared with -7 (median OS, 34 vs 17 months, p = 0.034). In multivariable analysis, blast count, TP53 mutations and number of mutations were independent predictors of OS, whereas the cytogenetic subgroups did not retain prognostic relevance. This study highlights the importance of mutational analysis in terms of prognosis in MDS patients with isolated -7 or del(7q).
引用
- Crisà E, Kulasekararaj AG, Adema V, et al. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia. 2020. PMID: 32066866. doi:10.1038/s41375-020-0728-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。